甲磺酸阿帕替尼片治疗化疗失败后转移性肝内胆管腺癌:1例病例报告  

Treatment with apatinib mesylate for metastatic intrahepatic cholangiocarcinoma after failure of chemotherapy:A report of 1 case

作　　者：王利叶 龚帅[1] 高丽萍 侯丽霞 何炜[1] WANG Liye;GONG Shuai;GAO Liping;HOU Lixia;HE Wei(Department of Oncology,First Affiliated Hospital of Zhengzhou University,Zhcngzhou 450052,Henan Province,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,河南郑州450052

出　　处：《肿瘤》2018年第11期1071-1076,共6页Tumor

摘　　要：目的:观察甲磺酸阿帕替尼片(简称:阿帕替尼)治疗化疗失败后转移性肝内胆管腺癌(intrahepatic cholangiocarcinoma,ICC)的疗效及安全性。方法:报道1例采用阿帕替尼治疗一线吉西他滨联合卡培他滨治疗失败的转移性ICC的方法、疗效及安全性。结果:阿帕替尼二线治疗晚期ICC无进展生存时间达到6个月。主要不良反应为面部水肿、高血压和晕厥,通过药物减量及对症治疗后得到控制。结论:阿帕替尼二线治疗该例晚期ICC有肯定的疗效,不良反应可耐受。需要大样本前瞻性的随机对照实验进一步确定阿帕替尼治疗ICC的疗效及安全性。Objective： To observe the efficacy and safety of apatinib mesylate tablets in the treatment of metastatic intrahepatic cholangiocarcinoma （ICC） after the failure of chemotherapy.Methods： One patient with metastatic ICC was treated with apatinib after failure of treatment with gerncitabine and capecitabine. The clinical efficacy of apatinib treatment and the major adverse reactions were recorded and analyzed.Results： For the patient with advanced ICC, apatinib as a second-line drug showed 6 month progression-free survival （PFS）. The major adverse reactions were facial edema, hypertension and syncope, which could be controlled by drug reduction and symptomatic treatment.Conclusion： Apatinib is effective in second-line treatment of advanced ICC, and the adverse effects are tolerated. However, the efficacy and safety of apatinib in the treatment of ICC need to be further confirmed by large sample size prospective randomized controlled trials （RCT）.

关 键 词：肝肿瘤 胆管上皮癌 阿帕替尼 血管生成抑制剂 治疗结果 

分 类 号：R737.9[医药卫生—肿瘤]